<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04265846</url>
  </required_header>
  <id_info>
    <org_study_id>20191129</org_study_id>
    <nct_id>NCT04265846</nct_id>
  </id_info>
  <brief_title>Prospective Clinical Study of Different Intraocular Lens Implantation Designed for the Correction of Presbyopia</brief_title>
  <official_title>Prospective Clinical Study of Different Intraocular Lens Implantation Designed for the Correction of Presbyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>People's Hospital of Guangxi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare postoperative Subjective and objective visual quality and economic efficiency of
      different Intraocular Lens(IOLs) implantation designed for the correction of presbyopia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compare postoperative Subjective and objective visual quality and economic efficiency of
      different Intraocular Lens Implantation designed for the correction of presbyopia.The
      subjects will undergo bilateral uneventful phacoemulsification and implantation of IOL.The
      subjects will be divided into several groups according to the type of the IOLs，including
      monofocal IOL group,monovision designed group ，bifocal IOL group, mix bifocal IOL
      group，trifocal IOL group，Exteded Depth of Focus(EDOF) IOL group and blend vision group.
      Compare the Subjective and objective visual quality and economic efficiency among these
      groups at 3 months postoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>monocular and binocular visual acuity</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>uncorrected distance visual acuity (UCVA), intermediate visual acuity, near visual acuity will be measured at 5m, 80cm and 40cm respectively. All visual acuity measurements will be conducted under photopic conditions (85 cd/m2) and at 100% contrast</description>
  </primary_outcome>
  <primary_outcome>
    <measure>economic efficiency</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>Compare the ratio of IOL cost to visual acuity among different groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Binocular Contrast sensitivity</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>Contrast sensitivity measures will be conducted binocularly, under photopic, mesopic (5 cd/m2), photopic with glare and mesopic with glare conditions, with the OPTEC 6500 contrast sensitivity test (Stereo Optical, USA). Contrast sensitivity will be evaluated at five spatial frequencies (1.5, 3, 6, 12, and 18 cycles per degree [cpd]). Patients will be allowed 5 minutes to adapt to each illumination level before testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binocular Defocus Curve</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>Binocular defocus curves will be obtained in all patients, positioned at 5m under photopic (&gt;85 cd/m 2 ) condition to measure the visual acuity with each defocus lens, representing the consecutive visual function of each eye. Negative lenses were added in 0.50 D steps and the visual acuity will be recorded for each type of defocus level. The procedure will be then repeated but with positive lenses. The range of defocus evaluated is from -4.00D to +2.00D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stereopsis</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>Use block diagram of random-spot synoptophore to observe long distance stereopsis vision and yan's stereogram to observe short distance stereopsis vision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fusion function</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>The fusion function of perception and movement (convergence and divergence)will be examined with a synoptophore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective visual quality</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>Photic phenomena (score according to severity,0~4, higher scores mean worse)and spectacle dependence percentages will be evaluated by questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Presbyopia</condition>
  <condition>Cataract Senile</condition>
  <arm_group>
    <arm_group_label>bifocal IOL group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The cataract patients who ask for bilateral phacoemulsification and bifocal IOLs implantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mix bifocal IOL group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The cataract patients who ask for phacoemulsification and mix different bifocal IOLs implantation bilaterally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trifocal IOL group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The cataract patients who ask for bilateral phacoemulsification and trifocal IOLs implantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDOF IOL group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The cataract patients who ask for bilateral phacoemulsification and EDOF IOLs implantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blend vision group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The cataract patients who ask for phacoemulsification and different IOLs implantation bilaterally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>monovision designed group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The cataract patients who ask for bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>monofocal IOL group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The cataract patients who ask for bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>bifocal IOL</intervention_name>
    <description>The patients will undergo bilateral phacoemulsification and bifocal IOLs implantation.</description>
    <arm_group_label>bifocal IOL group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>mix bifocal IOL</intervention_name>
    <description>The patients will undergo phacoemulsification and mix different bifocal IOLs implantation bilaterally.</description>
    <arm_group_label>mix bifocal IOL group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>trifocal IOL</intervention_name>
    <description>The patients will undergo bilateral phacoemulsification and trifocal IOLs implantation.</description>
    <arm_group_label>trifocal IOL group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EDOF IOL</intervention_name>
    <description>The patients will undergo bilateral phacoemulsification and EDOF IOLs implantation.</description>
    <arm_group_label>EDOF IOL group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>different IOLs</intervention_name>
    <description>The patients will undergo phacoemulsification and different IOLs implantation bilaterally.</description>
    <arm_group_label>blend vision group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>monofocal IOL</intervention_name>
    <description>The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.</description>
    <arm_group_label>monovision designed group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>monofocal IOL</intervention_name>
    <description>The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.</description>
    <arm_group_label>monofocal IOL group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with bilateral cataract

          -  Regular corneal topography and Preoperative corneal astigmatism ≤ 0.75 Diopter

        Exclusion Criteria:

          -  Pregnant or nursing women

          -  In the presence of other ocular diseases that may affect the stability of the lens
             capsule (pseudoexfoliation syndrome, glaucoma, traumatic cataract, Marfan syndrome,
             etc.)

          -  Pupil abnormality (non-reactive pupil, tonic pupils, abnormally shaped pupils, etc.)

          -  History of any clinically significant retinal pathology or ocular diagnosis (e.g.
             diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment,
             optic neuropathy optic nerv atrophy, amblyopia, strabismus, microphthalmos, aniridia,
             epiretinal membrane etc.) in the study eyes that could alter or limit final
             postoperative visual prognosis.

          -  Patients with history of ocular trauma or prior ocular surgery including refractive
             procedures

          -  postoperative visual acuity of worse than 0.2 logMAR in any eye

          -  Patients using systemic or ocular medication that affect visual acuity.

          -  Patients participating in other clinical trials during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qi Hong, PhD，MD</last_name>
    <role>Study Director</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qianqian Lan</last_name>
    <phone>+8618607711972</phone>
    <email>54283122@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Qi, MD</last_name>
      <email>doctorqihong@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 29, 2019</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

